Announcing two exciting OCRF-Funded Projects
The Ovarian Cancer Research Foundation (OCRF) is pleased to announce its support of two new significant research projects.
The OCRF is committed to funding innovative research of the highest quality as assessed by our international panel of scientific experts and our consumer representatives. The OCRF fills an otherwise unmet need by funding projects that are in their initial stages of research, where data needs to be built and research further developed prior to the clinical-trial stage.
High-grade serous ovarian carcinoma is the most common and aggressive type of ovarian cancer according to the State of the Nation in Ovarian Cancer: Research Audit conducted in 2020. Currently there are limited treatment options and patients often respond poorly to existing therapies, which can also have severe side effects. Ovarian cancer has a recurrence rate of 80 per cent, and limited treatment options mean that if the cancer recurs and is resistant to the limited available therapies, patients are left without a promising path forward. For this reason, the OCRF is thrilled to be supporting two new projects that are pursuing better treatment options for women and girls.
Exciting new research funded by the OCRF
The OCRF is pleased to be awarding funding to the below promising projects.
Associate Professor Ron Firestein was awarded over $238,000 toward his research that focuses on treatment.
Associate Professor Ron Firestein will lead a project that focuses on finding ways to disrupt the workings of the PAX8 (Paired-Box Gene 8) protein, which has been shown to increase the ability of cancer cells to grow and metastasize. Understanding how PAX8 can be reduced could provide insights into new potential treatment approaches. Read more about Associate Firestein's research.
Professor Matthias Ernst from the Olivia Newton-John Cancer Research Institute was awarded $299,000.
Professor Matthias Ernst will investigate an approach to improving patients response to treatment. His team seeks to determine if reducing the level of Hematopoietic Cell Kinase (HCK) protein in ovarian cancer patients, through a new approach to combination therapy, can improve the patients’ response to treatment. Read more about Associate Professor Ernst's research.
Why our funding model works
The OCRF exists to fund promising ovarian cancer research that has the potential to make the greatest impact for the greatest number of women. In a sector that has historically been underfunded, the OCRF fills the funding gap - providing seed funding to ovarian cancer projects that are in their initial stages of research, where data needs to be built to achieve ‘proof of concept’.
Early-stage research projects often do not qualify for grants from larger government funding bodies, such as the MRFF. Without the OCRF to fund and nurture these projects through to proof of concept, they would likely stagnate. We are proud to have seen OCRF-funded projects receiving funding from the Federal Government this year, supporting the assessments of our rigorous grants scheme led by an international panel of scientific experts and our consumer representatives.
Join the Lab, where real progress is made.
The Lab is a community of like-minded people coming together to provide a solid foundation of funding, each month, so that vital ovarian cancer research can continue uninterrupted. More than a monthly donation, it's a commitment to being there for every woman faced with ovarian cancer. It's stepping up to say you're invested in this mission, you're a part of the team that will make a difference.